What to Expect from this Patient and Family Webinar 

This webinar covers both the basics of diagnosis and early treatment as well as excitement around new immune therapies. The importance of expert management of infections is an area of particular focus. 

IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie will present Myeloma 101:  

• A discussion of MGUS, smoldering myeloma and active myeloma 
• Learn more about when patients may consider beginning treatment 
• Listen to presentation on tests for diagnosis and monitoring, how the disease is staged, and more

IMF Nurse Leadership Board Member Mary Steinbach, DNP, DPRN will be Taking the Reins of Your Multiple Myeloma Care:  

• Hear advice for side effects / symptom management 
• Outline the most common side effects / toxicities brought about by new and emerging therapies 

Rafat Abonour, MD will lead a segment on Frontline Therapy:

• Including a focus on autologous stem cell transplant 
• Discussion on triplets vs quadruplets in treatment 

Ajai Chari, MD will shed light on Relapse and New Immune Therapies:  

• Discussing the recent FDA approval of the first-in-class bispecific T-cell engager Tecvayli™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma
• Practical guidance will be provided regarding the many new myeloma treatment options, including the best sequencing of these options and their potential side effects
• Exploring the latest treatment options available in clinical trials today 

At the end of each presentation, participants will have time to ask questions  

Patient and Family Webinar Sponsors:

with support from:

AbbVie, Amgen, BMS, Genentech, GSK, Janssen, Karyopharm Therapeutics, Pfizer, Regeneron, Sanofi, Takeda Oncology, and The Binding Site

Please check out these multiple myeloma resources from our sponsors:
(All the sponsor links below are external links and you acknowledge that you are leaving the IMF website. The IMF is not responsible for content provided by the links below and you may be subject to the Privacy Policy and Terms & Conditions of the destination site(s).)

	Even The Odds
	REVLIMID My Disease and Treatment Digital Brochure POM My Disease and Treatment (pomalyst.com) Abecma-Patient-Brochure.pdf
	Genentech For Patients Ask Bigger Questions
	DARZALEX FASPRO® | DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) TECVAYLI™ (teclistamab-cqyv) CARVYKTI™ (ciltacabtagene autoleucel)
	Product website Learn About Our Mechanism of Action KaryForward, Our Patient Support Program
	Multiple Myeloma Told True MagnetisMM Clinical Research Studies Pfizer Clinical Trials
	A Guide to SARCLISA Talking to Your Healthcare Team The SARCLISA Conversation Starter
	Multiple Myeloma Resource Navigator for Patients PALs Understanding Your Multiple Myeloma Lab Values Leave Behind (English) PALs Understanding Your Multiple Myeloma Lab Values Leave Behind (Spanish)